Cancer Research Cancer Research Funding Available  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 3776-3782, July 15, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ross, D. D.
Right arrow Articles by Nora, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, D. D.
Right arrow Articles by Nora, R. E.

Estimation of Cell Survival by Flow Cytometric Quantification of Fluorescein Diacetate/Propidium Iodide Viable Cell Number1

Douglas D. Ross2, Christopher C. Joneckis, José V. Ordóñez, Allison M. Sisk, Richard K. Wu, Anne W. Hamburger and Richard E. Nora

Program of Oncology, University of Maryland Cancer Center [D. D. R., C. C. J., J. V. O., A. M. S., R. K. W., A. W. H., R. E. N.], the Department of Medicine, Division of Hematology [D. D. R.], and the Department of Pathology [A. W. H.], University of Maryland School of Medicine, Baltimore, Maryland

We report a flow cytometric method to quantify the number of viable cells remaining in suspension culture following exposure to cytotoxic drugs. Cell viability is assessed by flow cytometric measurement of cellular fluorescence after staining with fluorescein diacetate and propidium iodide in isotonic solution. The number of viable cells per ml of culture is determined by a timed count of viable cells and from knowledge of the flow cytometer sample flow rate. P388 murine or HL-60 human leukemia cells in culture were used as model systems. This method can quantify accurately viable cell concentrations in suspension culture from 100 cells/ml to 1 million cells/ml. The sensitivity of the method as a cytotoxicity assay increases if, following brief (1–4-h) exposure to drug, greater time is allowed for cell death and lysis to occur prior to flow cytometric counting of viable cells. If the viability assessment is deferred for at least 72 h following drug (daunorubicin, actinomycin D, vincristine) exposure, results were obtained approximating those obtained from the soft agar clonogenic assay or the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. In studying the cytotoxic effects of vincristine, actinomycin D, 1-ß-D-arabinofuranosylcytosine, and daunorubicin on P388 or HL-60 cells sensitive and resistant to these agents, reasonable results were obtained by flow cytometric counting of viable cell number. We have been able to perform this flow cytometric viability assay with ease using bone marrow blast cells obtained from patients with acute myelogenous leukemia. The method is facile, relatively rapid, and since it is ideal for studying cells in suspension culture, its potential as a predictor of chemotherapeutic response in leukemia warrants further evaluation.

1 Supported in part by Grant RO-1-CA40188 of NIH, National Cancer Institute (D. D. R.), and by the Medical Biotechnology Center of the Maryland Biotechnology Institute.

2 Special Fellow of the Leukemia Society of America. To whom requests for reprints should be addressed, at the University of Maryland Cancer Center, Bressler Research Building, Room 9-015, 655 West Baltimore Street, Baltimore, MD 21201.

Received 12/23/87. Revised 1/18/89. Revised 4/11/89. Accepted 4/19/89.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
K. Shiozawa, T. Nakanishi, M. Tan, H.-B. Fang, W.-c. Wang, M. J. Edelman, D. Carlton, I. Gojo, E. A. Sausville, and D. D. Ross
Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias
Clin. Cancer Res., March 1, 2009; 15(5): 1698 - 1707.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Ramachandran, G. Gopisetty, E. Gordian, L. Navarro, C. Hader, I. M. Reis, W. A. Schulz, and R. Singal
Methylation-Mediated Repression of GADD45{alpha} in Prostate Cancer and Its Role as a Potential Therapeutic Target
Cancer Res., February 15, 2009; 69(4): 1527 - 1535.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Frgala, O. Kalous, R. T. Proffitt, and C. P. Reynolds
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
Mol. Cancer Ther., March 1, 2007; 6(3): 886 - 897.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Nakanishi, K. Shiozawa, B. A. Hassel, and D. D. Ross
Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
Blood, July 15, 2006; 108(2): 678 - 684.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. Takebe, X. Cheng, T. E. Fandy, R. K. Srivastava, S. Wu, S. Shankar, K. Bauer, J. Shaughnessy, and G. Tricot
IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells.
Mol. Cancer Ther., February 1, 2006; 5(2): 457 - 466.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Salek-Ardakani, S. A. Lyons, and J. R. Arrand
Epstein-Barr Virus Promotes Human Monocyte Survival and Maturation through a Paracrine Induction of IFN-{alpha}
J. Immunol., July 1, 2004; 173(1): 321 - 331.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
Y. Umebayashi, Y. Miyamoto, M. Wakita, A. Kobayashi, and T. Nishisaka
Elevation of Plasma Membrane Permeability on Laser Irradiation of Extracellular Latex Particles
J. Biochem., August 1, 2003; 134(2): 219 - 224.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Nakanishi, J. E. Karp, M. Tan, L. A. Doyle, T. Peters, W. Yang, D. Wei, and D. D. Ross
Quantitative Analysis of Breast Cancer Resistance Protein and Cellular Resistance to Flavopiridol in Acute Leukemia Patients
Clin. Cancer Res., August 1, 2003; 9(9): 3320 - 3328.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. E. Karp, D. D. Ross, W. Yang, M. L. Tidwell, Y. Wei, J. Greer, D. L. Mann, T. Nakanishi, J. J. Wright, and A. D. Colevas
Timed Sequential Therapy of Acute Leukemia with Flavopiridol: In Vitro Model for a Phase I Clinical Trial
Clin. Cancer Res., January 1, 2003; 9(1): 307 - 315.
[Abstract] [Full Text] [PDF]


Home page
Appl. Environ. Microbiol.Home page
M. Graca da Silveira, M. Vitoria San Romao, M. C. Loureiro-Dias, F. M. Rombouts, and T. Abee
Flow Cytometric Assessment of Membrane Integrity of Ethanol-Stressed Oenococcus oeni Cells
Appl. Envir. Microbiol., December 1, 2002; 68(12): 6087 - 6093.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Zhang, Y. Xu, J. Gu, and S. F. Schlossman
A cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosis
PNAS, May 26, 1998; 95(11): 6290 - 6295.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.